We have some exciting news to share. Despite being on the market for less than a year, researchers just published a study citing our Immortalized Human Kidney Cancer Associated Fibroblasts (CAFs) (cat. CAF110-IM) for the first time.
The scientists investigated the therapeutic potential of the anti-fibroblast growth factor receptor 1 (FGFR1) monoclonal antibody OM-RCA-01. The presence of FGFR1 indicates a poor prognosis for patients with many cancers, including lung and renal cancers. In particular, FGFR1 can make immunotherapies against tumors less effective.
Image: When treated with the anti-CTLA-4 antibody (immunotherapy), the CAF-positive mice had a large tumor size. OM-RCA-01 was able to target both CAF-dependent and CAF-independent resistance to immunotherapy in the renal cancer in vivo model.
In the study, investigators developed several in vitro and in vivo assays to assess how OM-RCA-01 and immunotherapies impact tumors. In one of their models, the researchers cultured our immortalized kidney CAFs with CAF growth media (cat. CAFM03) before mixing them with Renca cells and implanting them into mice.
Across the many models, including the mice model with our CAFs, OM-RCA-01 combined with immunotherapy increases the efficacy of both treatments. You can read the complete study here.
Furthermore, as a reminder, all our human cells, including all of our CAFs, are 15% off this month. Learn more here.